Focus on orlistat: A nonsystemic inhibitor of gastrointestinal lipase for weight reduction in the management of obesity

Formulary

Volumn 33, Issue 10, 1998, Pages 943-959

  Reddy, Prabashni ^a   Chow, Moses S S ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0006321427     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kuczrnarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. JAMA 1994;272:205-11.
2. Bray GA. Health hazards of obesity. Endocrinol Metab Clin North Am 1996; 25:907-19.
3. Albu J, Allison D, Boozer CN, et al. Obesity solution: Report of a meeting. Nutr Rev 1997;55:150-6.
4. Wolf AN, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998;6:97-105.
5. Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996;36:1006-11.
6. Hauptmann JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992;55:309S-13S.
7. Schwizer W, Asal K, Kreiss C, et al. Role of lipase in the regulation of upper gastrointestinal function in humans. Am J Physiol 1997;273:G612-20.
8. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy volunteers. J Clin Pharmacol 1995;35:1103-8.
9. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month dose-ranging study. Eur J Clin Pharmacol 1994;54:125-32.
10. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-73.
11. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56:82-5.
12. Hussain Y, Güzelhan C, Odink J, et al. Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat. J Clin Pharmacol 1994;34:1121-5.
13. Güzelhan C, Odink J, Niestijl Jansen-Zuidema JJ, et al. Influence of dietary composition on the inhibition of fat absorption by orlistat. J Int Med Res 1994;22:255-65.
14. Tonstad S, Pometta D, Erkelens DW. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994;46:405-10.
15. Drent ML, van der Veen EA. Lipase inhibition: A novel concept in the treatment of obesity. Int J Obes 1993;17:241-4.
16. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study. Int J Obes 1995;19:221-6.
17. Drent ML, Popp-Snijders C, Ader HT, et al. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. Obes Res 1995;3:573-81.
18. James WP, Avenell A, Broom J, et al. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes 1997;21(Suppl 3):S24-S30.
19. Lucas C. A 2-year placebo-controlled study of orlistat in the treatment of obesity (abstract 0339). Diabetes 1997;46 (Suppl 1):86A.
20. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998;21:1288-94.
21. Steil CF. Diabetes mellitus. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 3rd ed. Stamford, CT: Appleton and Lange; 1997.
22. Luque CA, Rey JA, Fernandez A. Focus on sibutramine. Formulary 1997;32.1025-39.
23. Weintraub M, Hasday JD, Mushlin AL, et al. A double-blind clinical trial in weight control: Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984;144: 1143-8.
24. Meridia (sibutramine) package insert. Knoll Pharmaceutical Co, Mount Olive, NJ.
25. Froehlich F, Hartmann D, Guezelhan C, et al. Influence of orlistat on the regulation of gallbladder contraction in man. Dig Dis and Sci 1996;41:2404-8.
26. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996;18:1006-35.
27. Fried M, Schwizer W, Froehlich F, et al. Role of lipase in the regulation of upper gastrointestinal functions in man. Studies with THL - a new highly specific lipase inhibitor. Gastroenterology 1992;100: A272.
28. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996;36:647-53.
29. Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers. J Clin Pharmacol 1996;36:152-9.
30. Roche Xenical NDA withdrawal fits pattern of labeling negotiations between company and FDA; delay will allow media furor over obesity drugs to abate. F-D-C Reports "The Pink Sheet." September 1, 1997:15.
31. Xenical causal link to breast neoplasm cannot be ruled out - FDA. F-D-C Reports "The Pink Sheet." March 16, 1998:3.
32. Roche Xenical benefits quality of life, EU report states. F-D-C Reports "The Pink Sheet." August 17, 1998:15.
33. Roche's Xenical European labeling does not have breast cancer data. F-D-C Reports "The Pink Sheet." August 3, 1998:18.
34. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996;36:654-8.
35. Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995;35:840-3.
36. Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1996;36:659-66.
37. Hartmann D, Güzelhan C, Zuiderwijk PBM, Odink J. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996;50:421-4.
38. Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995;35:521-5.
39. Weber C, Tam YK, Schmidtke-Schrezenmeier G, et al. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996;51:87-90.
40. Guerciolini R. Mode of action of orlistat. Int J Obes 1997;21(Suppl 3):S12-S23.
41. Position paper of the North American Association for the Study of Obesity. Guidelines for the approval and use of drugs to treat obesity. Obes Res 1995;3:473-478.